Van Eck Associates Adds $3M in Biogen Inc. ($BIIB)
Van Eck Associates raised its Biogen Inc. holdings by 14,245 shares, totaling $233.3 million.
Key Points
- Van Eck Associates increased its Biogen Inc. stake by 14,245 shares, bringing its total to 1,079,861 shares, valued at $233.3 million.
- Biogen Inc. has a market cap of $31.89 billion and a P/E ratio of 23.25, with a 52-week range between $121.05 and $218.06.
- Insiders at Biogen made several recent purchases, and analysts have set new price targets, with some maintaining 'buy' ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Van Eck Associates has boosted its position in Biogen Inc. (NasdaqGS:BIIB) by adding 14,245 shares. This increase brings the fund's total holdings to 1,079,861 shares, valued at approximately $233.3 million, according to the latest Form 13F filing with the SEC. This data reflects the fund's holdings as of the end of the reporting period and may not represent its current position.
Van Eck Associates vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Van Eck Associates' Biogen Position
Van Eck Associates increased its stake in Biogen by 1.3%, adding 14,245 shares to its portfolio. The fund now holds 1,079,861 shares, up from 1,065,616 shares previously. The total value of these holdings is about $233.3 million.
Other Institutional Activity in Biogen
BlackRock, Inc. grew its holdings in Biogen by 1,163,231 shares, ending with 15,974,601 shares worth about $2.93 billion. FMR LLC added 3,381,678 shares, raising its total to 12,807,541 shares valued at $2.35 billion, marking a 35.9% increase. Vanguard Capital Management LLC opened a new position with 9,537,417 shares, valued at approximately $1.75 billion. State Street Corp made a slight increase of 8,902 shares, bringing its total to 7,167,922 shares, worth about $1.31 billion.
Biogen Inc. Stock Down 0.9%
Shares of Biogen Inc. (NasdaqGS:BIIB) traded near $216.03 on Sunday. The company has a market capitalization of $31.89 billion, with a P/E ratio of 23.25 and a forward P/E of 12.99. Biogen's beta is a low 0.177, indicating less volatility compared to the market. The stock's 52-week range is between $121.05 and $218.06, with a 50-day moving average of $193.05 and a 200-day moving average of $176.24. The company maintains a healthy current ratio of 3.07 and a quick ratio of 2.03, with a debt-to-equity ratio of 35.18.
$BIIB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Biogen reported revenue of $9.94 billion, showing a modest growth of 1.9%. The company achieved a net margin of 13.8% and a return on equity of 7.7%. Its earnings per share stood at $9.29. The next earnings report is expected on July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
On June 9, 2026, several insiders at Biogen Inc. made notable transactions. Menelas Pangalos bought 2,370 shares, while Eric Rowinsky and Stephen Sherwin each purchased 1,505 shares. Maria Freire acquired 2,005 shares on the same day. These transactions were not made under Rule 10b5-1 plans.
Analysts Set New Price Targets
On June 18, 2026, Morgan Stanley maintained a 'hold' rating with a $224 price target for Biogen. Mizuho reaffirmed its 'buy' rating on June 15, setting a target of $221. Needham upgraded its rating to 'buy' with a $255 target on June 8. RBC Capital maintained its 'buy' rating with a $227 target on May 27. Overall, the consensus recommendation is a 'buy' with an average target price of $220.25, based on 31 analyst opinions.
About Biogen Inc.
Biogen Inc. is a healthcare company based in Cambridge, Massachusetts. It focuses on discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company offers treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, among others. Biogen collaborates with various companies to enhance its research and development efforts. It was founded in 1978 and employs about 7,500 people under the leadership of CEO Christopher A. Viehbacher.
Bottom Line
Van Eck Associates' decision to increase its stake in Biogen Inc. suggests confidence in the company's future. Investors closely watch these filings to gauge institutional sentiment. It's important to remember that 13F filings are backward-looking and may not reflect current positions. Biogen's stable financials and ongoing insider activities continue to make it a company of interest in the healthcare sector.
Get Biogen Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIIB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.